Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies EMERYVILLE, Calif., Dec.

低成本融资利用XOMA于2021年斥资1400万美元收购VABYSMO®（faricimab）的特许权使用费，预计收益将用于股票回购和额外的特许权使用费和里程碑收购。蓝猫头鹰的融资扩展了XOMA作为新兴生物技术公司EMERYVILLE，California，12月的领先资本提供商的能力。

19, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced it entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc. (NYSE: OWL). “The Blue Owl financing provides us with significant non-dilutive capital to drive shareholder value through stock repurchases and additional royalty and milestone acquisitions,” stated Brad Sitko, Chief Investment Officer of XOMA.  “This capital infusion comes at an opportune time given the existing state of the biotech funding market, providing us with an opportunity to accelerate the growth of our royalty and milestones portfolio, which currently consists of two marketed products, two programs in or near registration, five assets in Phase 3 development, and over 60 assets in earlier stages of development.” “Blue Owl’s Life Science efforts are focused on credit, royalty, and equity investments in innovative healthcare and life sciences companies and products.  We recognize the value embedded in XOMA’s differentiated royalty and milestone aggregation business strategy.  Our long-established relationship with XOMA’s management team gives us confidence that they can continue building a balanced portfolio of current and future royalty-generating assets.  This financing establishes a long-term partnership with XOMA, as we help broaden th.

2023年19月19日（环球通讯社）--生物技术专利权使用费聚合商XOMA Corporation（纳斯达克代码：XOMA）今天宣布，它与Blue Owl capital Inc.（纽约证券交易所代码：Owl）的信贷平台管理的某些基金签订了一项无稀释、无追索权、专利权使用费支持的贷款，贷款金额高达1.4亿美元。XOMA首席投资官布拉德·西特科（BradSitko）表示：“蓝猫头鹰融资为我们提供了大量非稀释性资本，通过股票回购、额外的版税和里程碑收购来推动股东价值。”。“鉴于生物技术融资市场的现状，此次注资恰逢其时，为我们提供了一个加速版税和里程碑投资组合增长的机会，该投资组合目前包括两个上市产品、两个注册或接近注册的项目、五个三期开发资产和60多个早期开发资产。“”“蓝猫头鹰的生命科学工作专注于创新医疗保健和生命科学公司及产品的信贷、版税和股权投资。我们认识到XOMA差异化版税和里程碑聚合业务战略的价值。我们与XOMA管理团队的长期关系使我们相信他们可以继续建立平衡ed当前和未来产生版税的资产组合。这项融资与XOMA建立了长期合作关系，因为我们帮助扩大了th。